Ars Pharmaceuticals, INC Form 4 insider transactions

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on April 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on April 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed sales of 100,000 shares of common stock on April 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

RA Capital Management, L.P. and affiliated entities have increased their holdings in ARS Pharmaceuticals, Inc. through a series of open market purchases.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between March 22 and March 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed multiple sales of common stock between March 22 and March 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard E. Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between March 19 and March 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported multiple sales of common stock between March 19 and March 21, 2024, according to a recent SEC Form 4 filing.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between March 13 and March 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported the sale of common stock through a pre-arranged Rule 10b5-1 trading plan and adjustments in holdings through family trusts.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported the sale of common stock shares held directly and indirectly through trusts, as disclosed in a recent SEC Form 4 filing.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed sales of common stock on February 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported multiple sales of common stock between February 26 and February 28, 2024, according to a Form 4 filing with the SEC.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between February 26 and February 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.